New tool to speed cancer therapy approval available

Even though cancer remains a leading cause of death in America, it may take up to 12 years to introduce a new agent to fight cancer before the FDA and the success of the approval of only five to 10 percent. This means that the number of research hours and dollars wasted chasing avenues that do not bear fruit.
National Cancer Institute Translational Research Working Group (TRWG) developed a set of tools that it believes will improve the process. Tools, known as.
"Pathways to Clinical Goals" presented in the September 15 issue of Clinical Cancer Research, Journal of the American Association for Cancer Research.
"NCI supports a number of excellent translational research, but inefficiencies associated with lack of communication and coordination of efforts to prevent a number of promising leads to reach clinical trials and final approval," said Lynn Matrisian, Ph.D., Special Assistant to the Managing Director of the NCI. Matrisian co TRWG, which was formed in 2005 to accelerate the pace of translational cancer research. Publication of Pathways is expected to be a significant step forward in this process.
There are six ways, address the following categories: anti-cancer agents (drugs or biologics), biospecimen methods based on the assessment, immunomodulators, image-based environment assessment, intervention devices, and lifestyle changes.
Each path is a circuit with a series of steps to clarify and streamline the process of translational research. For example, in the way an agent to fight cancer, the researchers recommend that, first of all, consider the following three questions:There is an empirical basis for assigning clinical potential (alone and / or in combination) convincing?Lee provided the clinical need justify expenditure of funds?Is it feasible to identify / develop an agent against this target?
If the answer to any of these questions is "no," then research leaders are invited to send their research toward more effective plans.
Matrisian and her colleagues hope that TRWG path will be widely used and that they will do early translational research process more efficient.
"NCI funds a number of important research projects, and we hope that these ways will help in placing each research opportunity in the broader context of tangible cancer detection, diagnosis, prevention and treatment strategies. We believe with the experience of NCI" is an important resource for other groups to promote translational research as well, "said Matrisian.

A new class of cancer drugs in the adoption

A team of Vanderbilt University Medical Center researchers have developed a group of chemical compounds that may pose a new class of drugs for the treatment of cancer.
Compound the first selective inhibitor of protein phospholipase D (PLD), an enzyme that has been implicated in several human cancers including breast, kidney, stomach and colon.
New inhibitors, published in a recent issue of the journal Nature Chemical Biology, block invasive migration of breast cancer cells, supporting their further development as antimetastatic agents. They will also be useful tools for understanding the complex role of PLD in cell physiology, said N. Alex Brown, Ph.D., professor of pharmacology and one of the leaders of the team.
"PLD is associated with a number of fundamental cellular processes such as secretion, migration, growth and proliferation. But the lack of selective inhibitors indeed interfere with the ability of biologists to study this important enzyme," Brown said.
There are two related "isoforms" of PLD: PLD1 and PLD2. Both PLD enzymes produce phosphatidic acid, the key lipid metabolism and signaling molecule. But what if the two PLDs have different roles is an open question, which is a new isoform-selective inhibitors can now be used for the solution.
Brown and his colleagues found that PLD is important invasive migration of breast cancer cells in culture using a genetic tool called small interfering RNA (siRNA).
"When we had evidence of siRNA and other techniques that blocking PLD led to dramatic consequences blocking of metastatic invasion in breast cancer cells, we were very motivated to try to make the isoform-selective inhibitors," Brown said.
Craig Lindsley, Ph.D., a medicinal chemist who joined the faculty of Vanderbilt after five years at Merck Research Laboratories, and his group used a previously described inhibitor of PLD as a starting point for chemical process called diversity directed synthesis. The team screened the compounds obtained by the activity against PLD1 and PLD2 using in vitro and cell-screening tools developed in the laboratory of Brown.
"Without these high-quality screening tests and rapid turnover, this process is not going to work," said Lindsley, an associate professor of pharmacology and chemistry.Scientists were able to obtain compounds that selectively inhibits PLD1 or PLD2, and other compounds that inhibit both isoforms.
"With the connections we made, we can almost choose the range at which we would like to suppress the various isoforms, something that has never before been possible," Lindsley said.
Scientists have shown that the compounds act directly on the enzymes PLD (using purified proteins), and they showed that they blocked the invasive behavior of migration from three different lines of breast cancer.
"These inhibitors are key tools that we really have to probe biology, and we are obviously hoping to develop them for therapeutic use too," added Brown. "Not only did Craig excellent chemist, but he did not know that the compounds that have the potential to become drugs, and it was a very positive impact on this cooperation."
By focusing on FPGA, Brown, Lindsley, and their colleagues have the torch forward for the enzyme, which was famously characterized by Vanderbilt. John Exton, MD, Ph.D., professor of molecular physiology and biophysics and pharmacology, has been elected to the National Academy of Sciences for his work on PPB.
Scientists now will be to optimize their new compounds in vivo studies and give them characteristics consistent with being good medicine. They are also expanding their research in other areas of biology, in addition to studying inhibitors in models of breast cancer, they will learn how they work in cell systems that model of brain tumors, rheumatoid arthritis and viral infections.

Who Else Wants Insider hints on Cancers in men?

Lung Cancer JournalismThe most common cancer in men were in the order in respect of: prostate cancer, lung cancer and bowel cancer. Lung cancer and bowel cancer can occur in women, while prostate cancer is only on guys. Additional cancer, which will be just guys could possibly get would be testicular cancer, but it was seen as unusual and treatment is very good.
Lung cancer is just not as fashionable as prostate cancer, but it is much death and people who get lung cancer have an excellent treatment. In fact, with respect to 9 in 10 people said they could die of lung cancer from it. Upper protective equipment to stay away from lung cancer is, of course, do not smoke, and live a normal useful life. Lung cancer is actually very rare in non-smokers.
Bowel cancer entails the build-up inside the application, back, or possibly the gastrointestinal tract. The diagnosis is better than lung cancer, but it is important to analyze the conditions at an early stage before this spreads to the flesh. Reception is poor, for example, the set of exquisite meat, may increase the likelihood of developing colon cancer.
The most commonly cancer in men: prostate cancer
Prostate cancer is accumulated inside the gland, which may be glandular in male reproductive system, which will create smooth, and in relation to 20-30% relative to the volume of semen. It really is practically defined particularly in men, which you more than fifty years. This type of cancer usually grows slowly and does not cause just about any signs of the beginning. Men with prostate cancer for this reason usually die from other things before he actually diagnosed.
The most common symptoms of prostate cancer compared with the difficulties with the climax, erectile or possibly urine. So it will be recommended for older guys that experience these symptoms to see a doctor as soon as possible.
Most of the international space enough for you to display the screen for prostate cancer after reaching a particular guys are getting older, but research to evaluate the effectiveness of these types of tests showed that it was not possible to minimize mortality. Prostate cancer comes with a congenital problem, so if there is a genealogy and family history with the condition, it is wise to consider extra precautions.
Conclusion
Cancers of the kind usually obvious, the disease that we do not have to get it. Far better to hold to try to take few safety procedures, so that you can stay away from actually getting them. Lifestyle does not the biggest problem and the basic things that you can call to stop the cancer of as a rule, never smoke, eat a nutritious diet and do physical exercises. Another thing that was demonstrated in a recent study, to obtain critical is the preservation of useful vitamin D ranges. Read more other free information related to the symptoms of colon cancer in women, signs and symptoms of colon cancer in women and what are the symptoms of colon cancer in women

Cell phone-cancer link found

An Israeli scientist, Dr. Siegal Sadetzki, has found a link between cell phone usage and the development of tumors.

Dr. Sadetzki, a physician, epidemiologist and lecturer at Tel Aviv University, published the results of a study recently in the American Journal of Epidemiology, in which she and her colleagues observed that heavy cell phone users were subject to a higher risk of non-malignant and cancerous tumors of the salivary gland.

Those who used a cell phone heavily on the side of the head where the tumor developed were found to have an increased risk of about 50% for developing a tumor of the main salivary gland (parotid), in comparison to those who did not use cell phones.

The fact that the study was done on an Israeli population is significant. Says Sadetzki, Unlike people in other countries, Israelis were quick to adopt cell phone technology and have continued to be exceptionally heavy users. Therefore, the amount of exposure to radiofrequency radiation found in this study has been higher than in prior cell phone studies.

This unique population has given us an indication that cell phone use is linked to cancer, adds Sadetzki, whose study investigated nearly 500 people who had been diagnosed with non-malignant and cancerous tumors of the salivary gland.


Controlled Study Reveals Link
The studys subjects were asked to detail their cell phone use patterns in terms of how frequently they used one, and the average length of calls. They were in comparison to a sample of about 1,300 healthy control subjects.

The study also found an increased risk of cancer for heavy users who lived in rural areas. Due to fewer antennas, cell phones in rural areas need to emit more radiation to communicate effectively.

Sadetzki predicts that, over time, the greatest effects will be found in heavy users and children.

While anecdotal evidence has been substantial, the consistency of the results of this study support an association between cell phone use and these tumors. The risks have been hard to prove, mainly due to the long latency period involved in cancer development, explains Sadetzki.


Keep Calling but Call Smarter
Today it is estimated that more than 90% percent of the Western world uses cell phones. As the technology becomes cheaper and more accessible, its usage by a greater number of people, including children, is bound to increase.

While I think this technology is here to stay, Sadetzki says, I believe precautions should be taken in order to diminish the exposure and lower the risk for health hazards. She recommends that people use hands-free devices at all times, and when talking, hold the phone away from ones body. Less frequent calls, shorter in duration, should also have some preventative effect.

While she appreciates the ease of communication that cell phones allow between parents and their children, Sadetzki says that parents need to consider at what age their children start using them. Parents should be vigilant about their childrens using speakers or hands-free devices, and about limiting the number of calls and amount of time their children spend on the phone.

Some technology that we use today carries a risk. The question is not if we use it, but how we use it, concludes Sadetzki.

Sadetzkis main research on this new study was carried out at the Gertner Institute for Epidemiology and Health Policy Research at the Sheba Medical Center. Her research is part of the international Interphone Study, which attempts to determine an association between cell phones and several types of brain and parotid gland tumors. 

View the Original article

New class of cancer drugs in making

A team of Vanderbilt University Medical Center researchers has developed a group of chemical compounds that could represent a new class of drugs for treating cancer.

The compounds are the first selective inhibitors of the protein phospholipase D (PLD), an enzyme that has been implicated in multiple human cancers including breast, renal, gastric and colorectal.

The new inhibitors, published in the recent issue of Nature Chemical Biology, block the invasive migration of breast cancer cells, supporting their further development as antimetastatic agents. They will also be useful tools for understanding the complex roles of PLD in cellular physiology, said H. Alex Brown, Ph.D., professor of Pharmacology and one of the team leaders.

"PLD is linked to a number of fundamental cellular processes like secretion, migration, growth and proliferation. But the absence of selective inhibitors has really interfered with the ability of biologists to study this important enzyme," Brown said.

There are two related "isoforms" of PLD: PLD1 and PLD2. Both PLD enzymes produce phosphatidic acid, a key lipid metabolic and signaling molecule. But whether the two PLDs have different roles is an open question, one that the new isoform-selective inhibitors can now be used to address.

Brown and his colleagues had discovered that PLD was important to the invasive migration of breast cancer cells in culture using a genetic tool called small interfering RNA (siRNA).

"When we had evidence from siRNA and other methods that blocking PLD resulted in dramatic effects of blocking metastatic invasion of breast cancer cells, we were highly motivated to attempt to make isoform-selective inhibitors," Brown said.

Craig Lindsley, Ph.D., a medicinal chemist who joined the Vanderbilt faculty after five years at Merck Research Laboratories, and his group used a previously described PLD inhibitor as a starting point for a chemistry process called diversity-oriented synthesis. The team screened resulting compounds for activity against PLD1 and PLD2 using in vitro and cell-based screening tools developed in Brown's laboratory.

"Without these high quality screening assays and rapid turnaround, this process wouldn't have worked," said Lindsley, associate professor of Pharmacology and Chemistry. The scientists were able to generate compounds that selectively inhibited PLD1 or PLD2, and other compounds that inhibited both isoforms.

"With the compounds we've made, we can almost choose the range at which we'd like to inhibit the different isoforms, something that's never before been possible," Lindsley said.

The scientists demonstrated that the compounds act directly on the PLD enzymes (using purified proteins), and they showed that they blocked the invasive migration behavior of three different breast cancer cell lines.

"These inhibitors are the key tools we need to really probe the biology, and we're obviously hoping to develop them for therapeutic applications too," Brown added. "Not only is Craig an excellent chemist, but he really knows about making compounds that have the potential to become drugs, and that has had a very positive influence on this collaboration".

In focusing on PLD, Brown, Lindsley and their colleagues are carrying the torch forward for an enzyme that was famously characterized at Vanderbilt. John Exton, M.D., Ph.D., professor of Molecular Physiology & Biophysics and Pharmacology, was elected to the National Academy of Sciences for his work on PLDs.

The scientists will now optimize their new compounds for in vivo studies and to give them characteristics compatible with being good medications. They are also expanding their research into other areas of biology in addition to studying the inhibitors in breast cancer models, they will explore how they work in cell systems that model brain tumors, rheumatoid arthritis and viral infections. 

View the Original article